FDA approval of UCB’s Bimzelx gives the Belgian drugmaker a contender in the crowded plaque psoriasis therapies market. In the rare disease generalized myasthenia gravis, the agency approved Zilbrysq, a UCB drug with advantages over two blockbuster AstraZeneca drugs addressing the same target.
The FDA approved UCB’s Rystiggo for treating generalized myasthenia gravis. Drugs are already available for the rare neuromuscular disorder, but Rystiggo’s approval includes treatment of a subset of patients not addressed by other products.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The FDA cited manufacturing issues in turning down UCB’s application seeking approval for bimekizumab, an antibody drug developed to treat moderate-to-severe plaque psoriasis. Bimekizumab is already approved and available in other markets around world, but the FDA rejection delays UCB’s antibody drug from competing in the U.S. for now.
AbbVie has acquired Syndesi Therapeutics, an early clinical neuroscience startup developing drugs that have potential applications in a range of cognitive disorders. Syndesi is based on research from Belgian pharmaceutical company UCB.
Epilepsy is a small part of UCB’s neurology pipeline, but its proposed Zogenix acquisition would broaden the Belgium-based drugmaker's ability to address that market. Zogenix’s Fintepla is approved in the U.S. and Europe for a rare type of epilepsy called Dravet syndrome, and is in development for other rare epilepsies.
Novartis is paying UCB $150 million up front to share in the development of two clinical-stage Parkinson’s disease drugs that offer new approaches to treating the disease. Depending on the progress of those drugs, UCB could earn up to $1.5 billion in milestone payments.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The Belgian drugmaker will use Accenture's INTIENT Pharmacovigilance to monitor the safety of its drugs, including those that are on the market and in clinical trials. Germany's Bayer inked a similar deal with Genpact last year.
Results of the BE VIVID study showed that UCB's bimekizumab showed a statistically significant improvement in skin clearance compared with J&J's Stelara and placebo.
The Brussels-based drugmaker said the acquisition of Ra would boost its potential for leadership in the autoimmune disease myasthenia gravis, as both companies have drugs in Phase III development for it.
The company plans to the use the money to extend its reach into therapeutic area-related intelligence and outcomes-based contracting for payers.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
In less than a decade, the chief patient officer - and similar roles with different titles - has become a key part of the healthcare industry executive team.
One of the dominant themes at the Eye for Pharma conference this week has been how pharmaceutical companies can use social media channels beyond just conveying a positive message about their brands to their customers. But if traditional advertising doesn’t resonate enough and FDA regulatory concerns pour cold water on more innovative consumer interactions, how […]
Current medical news from today, including: UCB reaches settlement over off-label marketing of its epilepsy drug Keppra; the Food and Drug Administration warns of higher prostate cancer risks from baldness and prostate drugs; flu shots reach an all time high; and UCLA partners with Roche for stem cell and cancer research.
Generic drug company Synthon Pharmaceuticals has received tentative U.S. Food and Drug Administration approval on its application to make a version of UCB‘s (EBR:UCB) allergy medicine Xyzal. Netherlands-based Synthon, which has its U.S. headquarters and laboratories in Research Triangle Park, North Carolina, said it is seeking to bring a generic version of Xyzal oral solution […]